Clinical trials: Single Women
Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL.
- Conditions
- Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
- Trial name
- NCT03719443
- Testing
- VIS649
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Pharmacokinetics
Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol
The clinical phase I study aims at investigating the conversion of the contraceptive compound norethisterone within the body towards the contraceptive compound ethinylestradiol.
- Trial name
- NCT02170038
- Testing
- Microgynon, Noristerat(BAY86-6308)
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Drug Interactions
An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
The purpose of this study is to evaluate the effects of steady-state telotristat ethyl on the pharmacokinetics (PK) of single-dose fexofenadine in healthy subjects.
- Trial name
- NCT02157558
- Testing
- Fexofenadine, Telotristat etiprate
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Renal Cell Carcinoma
A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
This is a single center, Phase Ib study of Sunitinib and RAD001 in patients with advanced RCC. The study design is a phase I interpatient dose-escalation with a dose expansion at the maximum tolerated dose (MTD) in patients with…
- Trial name
- Rad/Sutent (NCT00788060)
- Testing
- Everolimus (RAD001), Sunitinib (Sutent)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Daniel George, MD
Advanced Malignancies
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v.
- Trial name
- NCT02608268
- Testing
- MBG453, PDR001, Decitabine
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Endometrial Cancer
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab…
- Trial name
- NCT05112991
- Testing
- Envafolimab+Lenvatinib, Envafolimab
- Where
- 19 sites in China
- Volunteers
- 108 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
HPV Associated Cancers, HIV (Human Immunodeficiency Virus)
CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV
This study is testing the immunotherapeutic agent, PDS0101, in adults living with HIV who are also infected with human papillomavirus (HPV) type 16.
- Conditions
- HPV Associated Cancers, HIV (Human Immunodeficiency Virus), Anal Cancer, Cervical Cancer
- Trial name
- NCT07090174
- Testing
- PDS0101
- Where
- 3 sites in United States, Puerto Rico
- Sponsor
- University of California, San Diego
Renal Impairment
Pharmacokinetics of LCQ908 in Patients With Renal Impairment
This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of renal impairment to healthy subjects
- Trial name
- NCT01558323
- Testing
- LCQ908
- Where
- 2 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Contraception
FC Patch Low: Metabolism Study
The aim of the present study is to investigate the effects of the transdermal patch on the parameters of hemostasis (blood clotting), lipid (fat), and carbohydrate (sugars) metabolism in healthy women who require contraception.
- Trial name
- NCT00933179
- Testing
- Gestodene/EE Patch (BAY86-5016), EE/Levonorgestrel (Microgynon, BAY86-4977)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects
This study is desgigned to look at the effect of multiple dosing administration of VI-0521 on Oral Contraceptive medication.
- Trial name
- NCT00821496
- Testing
- ethinyl estradiol, norethindrone, VI-0521
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Breast Cancer
ATAC - Pharmacokinetics (PK) Sub-Protocol
To assess the effect of ARIMIDEX on the pharmacokinetics of tamoxifen and the effects of tamoxifen on the pharmacokinetics of ARIMIDEX..
- Trial name
- NCT00784862
- Testing
- Anastrozole, Tamoxifen
- Volunteers
- 9,358 people
- Sponsor
- AstraZeneca
Cervical Cancer
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer
This is a phase II, prospective, single-arm, multicenter, open-label study to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with iparomlimab and tuvonralimab as neoadjuvant therapy in patients with…
- Trial name
- NCT07348861
- Testing
- Sacituzumab tirumotecan plus Iparomlimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zheng Min
Renal Artery Stenosis
Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the renal arteries.
- Trial name
- NCT00310557
- Testing
- Gadopentetate dimeglumine (Magnevist)
- Volunteers
- 116 people
- Sponsor
- Bayer
Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
This is a prospective, open-label, single arm, multi-centre interventional study to assess the clinical efficacy and safety of olaparib maintenance monotherapy and will be conducted in patients with platinum sensitive relapsed…
- Conditions
- Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive
- Trial name
- L-MOCA (NCT03534453)
- Testing
- Olaparib 300mg tablets
- Where
- 25 sites in China, Malaysia
- Volunteers
- 229 people
- Sponsor
- AstraZeneca
Healthy
Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.
Investigation of food effect on the bioavailability of a 25 mg empagliflozin tablet and assessment of dose proportionality between 10 mg and 25 mg empagliflozin tablets under fasting conditions.
- Trial name
- NCT01451775
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Contraception
Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study
The purpose of this study is to investigate whether bariatric surgery affects Drospirenone only pills absorption
- Trial name
- NCT06345560
- Testing
- Drospirenone
- Where
- Thailand
- Volunteers
- 16 people
- Sponsor
- Chulalongkorn University
Refractory Lupus Nephritis, Systemic Sclerosis
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren syndrome combined with pulmonary artery hypertension…
- Conditions
- Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension
- Trial name
- NCT06947473
- Testing
- umbilical cord blood CD19-BCMA CAR-T cells infusion
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing GoBroad Hospital
Healthy
A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food
The aim of this trial is to establish bioequivalence between EU-, US- and Japan-sourced Otezla® tablet formulations to assure comparability of results from Phase III trials of BI 730357 (new oral agent for treatment of psoriasis…
- Trial name
- NCT04811573
- Testing
- EU-sourced Otezla®, US-sourced Otezla®, Japan-sourced Otezla®
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Neoplasms, Non-small-cell Lung Cancer
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or…
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT06285097
- Testing
- PF-07820435, Sasanlimab
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 9 people
- Sponsor
- Pfizer
Infections Caused by Anaerobic Bacteria, Renal Impairment
Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment and Normal Renal Impairment
To evaluate the pharmacokinetics and safety of a single intravenous dose of levornidazole disodium phosphate for injection in subjects with moderate and severe renal impairment and healthy subjects.
- Trial name
- NCT07033182
- Testing
- Levornidazole Disodium Phosphate for Injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.